Selected 2003 Venture Capital Transactions as Company Counsel

Selected 2003 Venture Capital Transactions as Company Counsel

Publication

In 2003 we continue to represent more venture-backed companies in the eastern U.S. than any other law firm in the country. Representative transactions to date include the following:

  • Acopia Networks — $30 million
  • Alnylam Pharmaceuticals — $24.6 million
  • Ammasso — $10 million
  • Angiolink — $13.6 million
  • Ardais — $13.4 million
  • Axiowave Networks — $45 million
  • BioVex — $28 million
  • Blue Agave Software — $6 million
  • Compound Therapeutics — $12 million
  • Critical Therapeutics — $56 million
  • Deploy Solutions — $21 million
  • EM4 — $8 million
  • Endius — $26.5 million
  • Evident Software — $6.8 million
  • Eyetech Pharmaceuticals — $25 million
  • Eziba — $3.8 million
  • GenPath Pharmaceuticals — $42.7 million
  • Idenix Pharmaceuticals — $255 million
  • Incipient — $25 million
  • IntelliVid — $5.5 million
  • Jedai Broadband Networks — $10 million
  • Linguagem — $10.2 million
  • LiveVault — $10 million
  • Momenta Pharmaceuticals — $19 million
  • Nantero — $10.5 million
  • Neothermia — $13.1 million
  • Netezza — $20 million
  • Netilla Networks — $5 million
  • Optiant — $10.5 million
  • Performaworks — $13 million
  • Princeton eCom — $5 million
  • Quallaby — $5 million
  • Quantum Bridge Communications — $20 million
  • Starent Networks — $23 million
  • Storability — $7 million
  • Tazz Networks — $10.5 million
  • VistaPrint — $30 million
  • Water Cove Networks — $20 million

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.